Sponsored Links
| Enzon Announces Discontinuation Of PEG-SN38 Program In Metastatic Colorectal Carcinoma In Light Of Evolving Standards Of Care |
 |
 |
 |
| Medical News - Colorectal Cancer | |||
|
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study... Read more: Colorectal Cancer News From Medical News Today
|